Kevin M. Motz

Kevin M. Motz

Auto-generated profile, based on publicly available information

Kevin M. Motz

Department of Otolaryngology – Head and Neck Surgery Johns Hopkins University School of Medicine Baltimore Maryland USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2020 in The Laryngoscope
Verified
Journal Article
Closed access
PDF file
KMKevin Motz
Kevin Motz
ILIoan A Lina
Ioan A Lina
MMMichael K. Murphy
Michael K. Murphy
VDVirginia Drake
Virginia Drake
RDRuth Davis
Ruth Davis
AHAlexander Hillel
Alexander Hillel

8 June 2023 in JCI Insight
Verified
Journal Article
Open access
PDF file
KMKevin M. Motz
Kevin M. Motz
ILIoan A Lina
Ioan A Lina
ISIdris Samad
Idris Samad
MMMichael K. Murphy
Michael K. Murphy
MDMadhavi Duvvuri
Madhavi Duvvuri
AHAlexander T. Hillel
Alexander T. Hillel
Laryngotracheal stenosis (LTS) is pathologic fibrotic narrowing of the larynx and trachea characterized by hypermetabolic fibroblasts and CD4 + T cell–mediated inflammation. However, the role of CD4 + T cells in promoting LTS fibrosis is unknown. The mTOR signaling pathways have been shown to regulate the T cell phenotype. Here we investigated the influence of mTOR signaling in CD4 + T cells on LTS pathogenesis. In this study, human LTS specimens revealed a higher population of CD4 + T cells expressing the activated isoform of mTOR. In a murine LTS model, targeting mTOR with systemic sirolimus and a sirolimus-eluting airway stent reduced fibrosis and Th17 cells. Selective deletion of mTOR in CD4 + cells reduced Th17 cells and attenuated fibrosis, demonstrating CD4 + T cells’ pathologic role in LTS. Multispectral immunofluorescence of human LTS revealed increased Th17 cells. In vitro, Th17 cells increased collagen-1 production by LTS fibroblasts, which was prevented with sirolimus pretreatment of Th17 cells. Collectively, mTOR signaling drove pathologic CD4 + T cell phenotypes in LTS, and targeting mTOR with sirolimus was effective at treating LTS through inhibition of profibrotic Th17 cells. Finally, sirolimus may be delivered locally with a drug-eluting stent, transforming clinical therapy for LTS.

10 February 2022 in The Laryngoscope
Verified
Journal Article
Open access
PDF file
ILIoan A Lina
Ioan A Lina
HTHsiu‐Wen Tsai
Hsiu‐Wen Tsai
ABAlexandra J. Berges Bs
Alexandra J. Berges Bs
RORafael A. Ospino
Rafael A. Ospino
RDRuth J. Davis
Ruth J. Davis
AHAlexander T. Hillel
Alexander T. Hillel
Objective: Characterize and quantify epithelium in multiple etiologies of laryngotracheal stenosis (LTS) to better understand its role in pathogenesis.Study Design: Controlled in vitro cohort study.Methods: Endoscopic brush biopsy samples of both normal (non‐scar) and scar were obtained in four patients with idiopathic subglottic stenosis (iSGS) and four patients with iatrogenic LTS (iLTS). mRNA expression of basal, ciliary, and secretory cell markers were evaluated using quantitative PCR. Cricotracheal resection tissue samples (n = 5 per group) were also collected, analyzed using quantitative immunohistochemistry, and compared with rapid autopsy tracheal samples.Results: Both iSGS and iLTS‐scar epithelium had reduced epithelial thickness compared with non‐scar control epithelium (P = .0009 and P = .0011, respectively). Basal cell gene and protein expression for cytokeratin 14 was increased in iSGS‐scar epithelium compared with iLTS or controls. Immunohistochemical expression of ciliary tubulin alpha 1, but not gene expression, was reduced in both iSGS and iLTS‐scar epithelium compared with controls (P = .0184 and P = .0125, respectively). Both iSGS and iLTS‐scar had reductions in Mucin 5AC gene expression (P = .0007 and P = .0035, respectively), an epithelial goblet cell marker, with reductions in secretory cells histologically (P < .0001).Conclusions: Compared with non‐scar epithelium, the epithelium within iSGS and iLTS is morphologically abnormal. Although both iSGS and iLTS have reduced epithelial thickness, ciliary cells, and secretory cells, only iSGS had significant increases in pathological basal cell expression. These data suggest that the epithelium in iSGS and iLTS play a common role in the pathogenesis of fibrosis in these two etiologies of laryngotracheal stenosis.Setting: Tertiary referral center (2017–2020).Level of Evidence: NA Laryngoscope, 132:2194–2201, 2022

13 July 2021 in Otolaryngology–Head and Neck Surgery
Verified
Journal Article
Open access
PDF file
RDRuth J. Davis
Ruth J. Davis
ILIoan A Lina
Ioan A Lina
KMKevin Motz
Kevin Motz
AGAlexander Gelbard
Alexander Gelbard
RLRobert R. Lorenz
Robert R. Lorenz
AHAlexander T. Hillel
Alexander T. Hillel
Objective: To describe technical aspects and surgical outcomes of endoscopic resection and mucosal reconstitution with epidermal grafting (ie, the Maddern procedure) in the treatment of idiopathic subglottic stenosis.Study Design: Medical record abstraction.Setting: Johns Hopkins Hospital.Methods: Retrospective series of 9 adults with idiopathic subglottic stenosis who underwent the Maddern procedure by a single surgeon over a 5‐year period. Prespecified outcomes included (1) perioperative outcomes (Clavien‐Dindo grade 4/5 complications, need for staged tracheostomy, hospital length of stay), (2) postoperative outcomes (peak expiratory flow rate [PEFR], need for subsequent airway surgery, tracheostomy at follow‐up), and (3) patient‐reported quality‐of‐life outcomes (Clinical COPD Questionnaire, Voice Handicap Index–10, Eating Assessment Tool–10, and 12‐Item Short Form Version 2). Wilcoxon matched‐pairs signed rank test and Kaplan‐Meier analysis were performed.Results: There were no Clavien‐Dindo grade 4/5 complications; 2 patients required unplanned staged tracheostomy; and the median length of stay was 3 days. Following endoscopic resection and stent removal, a median of 2 laser resurfacing procedures were required. Two patients developed recurrent stenosis requiring cricotracheal resection (CTR). There were significant improvements in PEFR, Clinical COPD Questionnaire, and Voice Handicap Index–10, without significant difference in Eating Assessment Tool–10. The 12‐Item Short Form Version 2 approximated the population norm. Kaplan‐Meier analysis demonstrated significant improvement in time to surgery after the final laser resurfacing.Conclusion: The Maddern procedure has a low complication rate and offers durable physiologic improvement in PEFR, limiting need for additional procedures. Risks included need for CTR salvage, temporary tracheostomy, phlegm accumulation, and laryngospasm. It is a surgical option for patients with short dilation intervals who prefer to avoid the risks of CTR.

1 November 2017 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Open access
PDF file
KMKevin Motz
Kevin Motz
ISIdris Samad
Idris Samad
LYLinda X. Yin
Linda X. Yin
MMMichael K. Murphy
Michael K. Murphy
MDMadhavi Duvvuri
Madhavi Duvvuri
AHAlexander T. Hillel
Alexander T. Hillel
Laryngotracheal stenosis (LTS) is a critical narrowing of the glottis, subglottis, and/or trachea secondary to the development of pathologic fibrosis or scar. Laryngotracheal stenosis is most commonly a result of postintubation injury but can also be autoimmune related, radiation induced, or idiopathic.1,2 The multiple consequences of LTS include communication handicap and airway obstruction, a potentially life-threatening complication if not managed appropriately.1,3 The contemporary management of LTS is primarily surgical and includes serial dilation, tracheal or cricotracheal resection, laryngotracheoplasty, and/or permanent tracheostomy.4,5 Medical therapies available for the management of LTS are limited, reflecting a need for improved understanding of disease pathogenesis.

31 March 2016 in Current Otorhinolaryngology Reports
Verified
Journal Article
Closed access
PDF file
KMKevin M. Motz
Kevin M. Motz
AHAlexander T. Hillel
Alexander T. Hillel